Bio-Path posts Q2 2024 net loss of $1.9M; cash position improves to $4.0M

BIO-PATH HOLDINGS, INC.

2024-Q2 EPS reported -$4.45

Net loss of $1.9M ($1.16 per share) vs $4.2M ($10.64 per share) in Q2 2023.
Cash $4.0M at June 30, 2024, up from $1.1M at Dec 31, 2023; operating cash burn $4.3M.
Closed $4.0M private placement in June: 1.8M shares + warrants at $2.21/share.
R&D expense down to $1.9M from $3.1M; G&A flat at $1.2M.
Presented interim Phase 2 data for prexigebersen in AML at ASCO and EHA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.